Compare Recursion Pharmaceuticals Inc (RXRX) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Toyota Motor Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B), while Toyota Motor Corp trades at $184.37 (market cap $216.99B). The key difference: Toyota Motor Corp is far larger — about 93.9× Recursion Pharmaceuticals Inc's market cap, and Toyota Motor Corp pays a 3.43% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Toyota Motor Corp for 116 Days on average.
| RXRX | TM | |
|---|---|---|
Market Cap | $2.31B | $216.99B |
Volume | 40,478,768 | 314,929 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $248.29 |
52-Week Low | $2.84 | $166.50 |
Typical Hold Time | 22 Days | 116 Days |
Enterprise Value | $1.83B | $410.32B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Toyota Motor trades at $182.91, down 1.43% with bearish technical signals but attractive valuation metrics including P/E of 8.22 and P/B of 0.92. The company reported strong Q2 2026 earnings beat with EPS of $7.57 versus $4.68 expected, though revenue growth has moderated to 6.5% year-over-year. Recent news highlights Toyota's expanding electrified vehicle lineup and U.S. market share gains, while facing production challenges from Thailand floods and China sales weakness.
Toyota presents a value opportunity with solid profitability (8.63% net margin) and consistent earnings beats, but faces near-term headwinds from production disruptions and competitive pressures. Analyst consensus leans cautious with 62.5% hold ratings, suggesting the stock may consolidate near current levels despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
